262 related articles for article (PubMed ID: 15122082)
1. A phase II study of high-dose 24 hour continuous infusion 5-FU and leucovorin and low-dose PALA for patients with advanced pancreatic adenocarcinoma: a Southwest Oncology Group Study.
Whitehead RP; Benedetti JK; Abbruzzese JL; Ardalan B; Goodwin JW; Balcerzak SP; Samlowski WE; Lenz HJ; Macdonald JS
Invest New Drugs; 2004 Aug; 22(3):335-41. PubMed ID: 15122082
[TBL] [Abstract][Full Text] [Related]
2. A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study.
Whitehead RP; Benedetti JK; Abbruzzese JL; Ardalan B; Williamson S; Gaynor ER; Balcerzak SP; Macdonald JS
Invest New Drugs; 2004 Nov; 22(4):467-73. PubMed ID: 15292717
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of low dose N-phosphonacetyl-L-aspartic acid and high dose 5-fluorouracil administered concomitantly with radiation therapy for unresectable localized adenocarcinoma of the pancreas.
Ardalan B; Ucar A; Reddy R; Livingstone AS; Markoe A; Schwade J; Richman SP; Donofrio K
Cancer; 1994 Oct; 74(7):1869-73. PubMed ID: 8082092
[TBL] [Abstract][Full Text] [Related]
4. A phase I, II study of high-dose 5-fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
Ardalan B; Sridhar KS; Benedetto P; Richman S; Waldman S; Morrell L; Feun L; Savaraj N; Fodor M; Livingstone A
Cancer; 1991 Sep; 68(6):1242-6. PubMed ID: 1873776
[TBL] [Abstract][Full Text] [Related]
5. A phase II multi-institutional trial of low-dose N-(phosphonacetyl)-L-aspartate and high-dose 5-fluorouracil as a short-term infusion in the treatment of adenocarcinoma of the pancreas. A Southwest Oncology Group study.
Morrell LM; Bach A; Richman SP; Goodman P; Fleming TR; MacDonald JS
Cancer; 1991 Jan; 67(2):363-6. PubMed ID: 1985731
[TBL] [Abstract][Full Text] [Related]
6. A phase I study of continuous infusion 5-fluorouracil plus calcium leucovorin in combination with N-(phosphonacetyl)-L-aspartate in metastatic gastrointestinal adenocarcinoma.
Grem JL; McAtee N; Steinberg SM; Hamilton JM; Murphy RF; Drake J; Chisena T; Balis F; Cysyk R; Arbuck SG
Cancer Res; 1993 Oct; 53(20):4828-36. PubMed ID: 8402669
[TBL] [Abstract][Full Text] [Related]
7. Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer.
Kemeny N; Conti JA; Seiter K; Niedzwiecki D; Botet J; Martin D; Costa P; Wiseberg J; McCulloch W
J Clin Oncol; 1992 May; 10(5):747-52. PubMed ID: 1569447
[TBL] [Abstract][Full Text] [Related]
8. Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cancer and Leukemia Group B Study.
O'Dwyer PJ; Manola J; Valone FH; Ryan LM; Hines JD; Wadler S; Haller DG; Arbuck SG; Weiner LM; Mayer RJ; Benson AB
J Clin Oncol; 2001 May; 19(9):2413-21. PubMed ID: 11331320
[TBL] [Abstract][Full Text] [Related]
9. Treatment of advanced adenocarcinomas of the exocrine pancreas and the gallbladder with 5-fluorouracil, high dose levofolinic acid and oral hydroxyurea on a weekly schedule. Results of a multicenter study of the Southern Italy Oncology Group (G.O.I.M.).
Gebbia V; Majello E; Testa A; Pezzella G; Giuseppe S; Giotta F; Riccardi F; Fortunato S; Colucci G; Gebbia N
Cancer; 1996 Sep; 78(6):1300-7. PubMed ID: 8826954
[TBL] [Abstract][Full Text] [Related]
10. Phase I study of phosphonacetyl-L-aspartate, 5-fluorouracil, and leucovorin in patients with advanced cancer.
Hageboutros A; Rogatko A; Newman EM; McAleer C; Brennan J; LaCreta FP; Hudes GR; Ozols RF; O'Dwyer PJ
Cancer Chemother Pharmacol; 1995; 35(3):205-12. PubMed ID: 7805178
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer.
Rosvold E; Schilder R; Walczak J; DiFino SM; Flynn PJ; Banerjee TK; Heim WJ; Engstrom PF; Ozols RF; O'Dwyer PJ
Cancer Chemother Pharmacol; 1992; 29(4):305-8. PubMed ID: 1537077
[TBL] [Abstract][Full Text] [Related]
12. N-(phosphonacetyl)-L-aspartate and calcium leucovorin modulation of fluorouracil administered by constant rate and circadian pattern of infusion over 72 hours in metastatic gastrointestinal adenocarcinoma.
Grem JL; Yee LK; Schuler B; Hamilton JM; Chen AP; Chabuk C; Grollman F; Grabenc M; Allegra CJ; Takimoto CH
Ann Oncol; 2001 Nov; 12(11):1581-7. PubMed ID: 11822758
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of low-dose N-(phosphonacetyl)-disodium L-aspartic acid and high-dose 24-hour infusional 5-fluorouracil in advanced gastric adenocarcinoma. A Southwest Oncology Group study.
Martino RL; Fleming TR; Morrell LM; Ardalan B; Richman SP; Macdonald JS
Invest New Drugs; 1996; 14(4):419-21. PubMed ID: 9157080
[TBL] [Abstract][Full Text] [Related]
14. Phase I study of high dose 5-fluorouracil and high dose Leucovorin with low dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies.
Ardalan B; Stridhar K; Reddy R; Benedetto P; Richman S; Waldman S; Morrell L; Feun L; Savaraj N; Livingstone A
Int J Radiat Oncol Biol Phys; 1992; 22(3):511-4. PubMed ID: 1735689
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer.
O'Dwyer PJ; Paul AR; Walczak J; Weiner LM; Litwin S; Comis RL
J Clin Oncol; 1990 Sep; 8(9):1497-503. PubMed ID: 2391557
[TBL] [Abstract][Full Text] [Related]
16. A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers.
Ardalan B; Singh G; Silberman H
J Clin Oncol; 1988 Jun; 6(6):1053-8. PubMed ID: 3373260
[TBL] [Abstract][Full Text] [Related]
17. Sequential biochemical modulation of fluorouracil with folinic acid, N-phosphonacetyl-L-aspartic acid, and interferon alfa-2a in advanced colorectal cancer.
Royce ME; McGarry W; Bready B; Dakhil SR; Belt RJ; Goodwin JW; Gray R; Hoff PM; Winn R; Pazdur R
J Clin Oncol; 1999 Oct; 17(10):3276-82. PubMed ID: 10506630
[TBL] [Abstract][Full Text] [Related]
18. Biomodulation of Fluorouracil in colorectal cancer.
Ardalan B; Luis R; Jaime M; Franceschi D
Cancer Invest; 1998; 16(4):237-51. PubMed ID: 9589033
[TBL] [Abstract][Full Text] [Related]
19. [5-FU, folinic acid and cisplatin (LV5FU2-P) for unresectable pancreatic cancer].
Taïeb J; Lecomte T; Ezenfis J; Artru P; Mitry E; Boige V; Clavero-Fabri MC; Vaillant JN; Rougier P; Ducreux M
Gastroenterol Clin Biol; 2002; 26(6-7):605-9. PubMed ID: 12193860
[TBL] [Abstract][Full Text] [Related]
20. Effects of 5-fluorouracil and leucovorin in the treatment of pancreatic-biliary tract adenocarcinomas.
Choi CW; Choi IK; Seo JH; Kim BS; Kim JS; Kim CD; Um SH; Kim JS; Kim YH
Am J Clin Oncol; 2000 Aug; 23(4):425-8. PubMed ID: 10955877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
